Trial
NCT05215951
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Lung Cancer
Intervention
osimertinib
Why stopped
Enrollment delay study timeline seriously.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-15